Alle Studien
AutorisiertTherapeutische Bestätigung (Phase III)Interventionell

Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3

This study is looking at a new medicine called stiripentol for people aged 6 and older who have primary hyperoxaluria (PH). PH is a rare condition that affects the kidneys and can lead to kidney stones. The main goal is to see if stiripentol helps lower the amount of a substance called oxalate in the urine over 6 months. Researchers also want to check if the medicine is safe and if it improves kidney health and overall well-being. Participants will receive either the active medicine or a placebo (a dummy pill) to compare the effects.

Auf einen Blick

Status
Autorisiert
Phase
Therapeutische Bestätigung (Phase III)
Sponsor
Biocodex
Einschreibeziel
19
Starten
16. Mai 2024

Worum geht es in dieser Studie?

This study is a phase 3 clinical trial, which means it's one of the final steps in testing a new medicine before it can be considered for wider use. It's focused on a condition called primary hyperoxaluria (PH). This is a rare, inherited disorder where the body produces too much oxalate, a natural chemical. This excess oxalate can build up and form painful kidney stones, or even lead to serious kidney damage over time.

The medicine being tested is called stiripentol, and it's thought to help reduce these high oxalate levels. Researchers will be carefully comparing stiripentol to a 'placebo' – a pill that looks the same but contains no active medicine. This helps them understand if any changes they see are truly due to the stiripentol or something else.

The main thing the study wants to find out is how much stiripentol can lower the amount of oxalate in people's urine over six months. They'll also be looking at other important things, like how well the kidneys are working, if stiripentol reduces kidney stone problems, and how people's quality of life changes while taking the medicine. This is a crucial step to see if stiripentol could become a helpful treatment for people living with primary hyperoxaluria.

Wichtige Erkenntnisse

  • This study is for people aged 6 and over with primary hyperoxaluria (PH).
  • It's testing a medicine called stiripentol to lower oxalate in urine.
  • Participants will take either stiripentol or a dummy pill (placebo).
  • The study lasts 6 months and includes regular clinic visits.
  • Potential benefits include access to a new medicine, but there are also potential risks.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

This study is looking for both adults and children aged 6 years and older who have been diagnosed with primary hyperoxaluria (this includes types 1, 2, or 3). Both men and women can take part. There is no upper age limit for adults wanting to join the study.

To ensure the study is safe and the results are clear, there will be specific health checks and medical history questions to see if the study is suitable for you or your child. For example, certain other medical conditions or medicines you are currently taking might mean you can't participate.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you or your child aged 6 years or older?
  2. Do you have a confirmed diagnosis of primary hyperoxaluria (PH1, PH2, or PH3)?
  3. Are you able to attend regular clinic appointments for 6 months?
  4. Are you willing to take study capsules and have blood and urine tests?
  5. Do you understand that you might receive a placebo?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you will be given either the study medicine (stiripentol) or a placebo (a dummy pill) in capsule form. You will need to take these pills regularly as instructed. Over the course of the study, you will have several visits to the clinic. These visits will involve various tests and assessments, such as urine collections over 24 hours to measure oxalate levels, blood tests to check kidney function, and possibly questions about your general health and how you are feeling.

The study will last for a total of 6 months. During this time, the researchers will carefully monitor your health and how the treatment is affecting you. There will also be follow-up appointments to ensure everything is going well and to collect all necessary information. Be prepared for regular contact with the study team and committing to the scheduled appointments.

Potenzielle Risiken und Vorteile

Taking part in a study like this might offer potential benefits, such as gaining access to a new medicine that could help manage your primary hyperoxaluria before it's widely available. You'll also receive close medical attention and monitoring from a specialist team. However, there are potential risks, including side effects from the medicine – though these will be carefully monitored. There's also a chance you might receive the placebo and not the active medicine. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (3)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Frankreich
  • —
    Unbestätigt
    Belgien
  • —
    Unbestätigt
    Italien

Häufige Fragen

What is primary hyperoxaluria (PH)?

It's a rare inherited kidney condition where your body makes too much oxalate, which can lead to kidney stones and kidney damage.

What is stiripentol?

It's the name of the medicine being tested in this study to see if it can help reduce high oxalate levels.

Was bedeutet 'Placebo'?

A placebo is a pill that looks like the study medicine but doesn't contain any active ingredients. It helps researchers compare the effects accurately.

Wie lange wird die Studie dauern?

The main part of the study will last for 6 months.

Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?

No, during the study, neither you nor your doctor will know whether you are receiving the active medicine or the placebo. This is standard practice to ensure fair results.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.